PCMP-H66 Antibody

What is PCMP-H66 Antibody and what is its target antigen?

PCMP-H66 Antibody (product code CSB-PA915819XA01DOA) is a research antibody designed for laboratory investigations only . While specific target information for PCMP-H66 is limited in current literature, monoclonal antibodies typically target specific epitopes on proteins of interest. For instance, comparable research antibodies have been developed against targets like plasminogen-activating enzymes with molecular weights of 66,000 (66 K, HPA66) and viral hemagglutinin (HA) proteins .

When working with PCMP-H66 Antibody, researchers should perform thorough validation studies to confirm its specificity for the intended target. This typically involves multiple complementary techniques including:

• Western blotting with positive and negative control samples

• Immunofluorescence assays with transfected and non-transfected cells

• ELISA binding assays with purified target protein

• Competitive binding assays with known ligands

How should researchers validate PCMP-H66 Antibody before experimental use?

Comprehensive validation of PCMP-H66 Antibody should follow a multi-technique approach:

• Specificity testing: Screen against a panel of related and unrelated proteins to confirm specific recognition of the target antigen. This approach was demonstrated with other monoclonal antibodies that showed no binding to "a variety of other plasminogen activators, including 52-K and 36-K human enzymes and 48-K and 75-K murine enzymes" .

• Method-specific validation: For each application (IFA, Western blot, ELISA), perform separate validation studies with appropriate controls. For example, in studies of anti-HA antibodies, researchers used "enzyme-linked immunosorbent assay (ELISA) using 96-well microtiter plates coated with inactivated SZ19 virus" to determine antibody titer .

• Cross-reactivity assessment: Test against samples from multiple species if cross-reactivity is expected or desired.

• Binding characteristics determination: Measure critical parameters like affinity constants. For reference, some well-characterized antibodies have binding constants of approximately "2.5 × 10^9 l/mol" .

• Functional validation: If applicable, determine if the antibody modulates the function of its target protein through inhibition assays.

What experimental techniques are compatible with PCMP-H66 Antibody?

While specific application data for PCMP-H66 Antibody is limited, research antibodies are typically validated for multiple techniques. Based on methodologies used with comparable research antibodies, PCMP-H66 may be applicable to:

• Western blotting: For detecting denatured proteins in cell or tissue lysates, as demonstrated with other antibodies that "recognize the HA and/or HA1 protein from lysed virus particles" .

• Immunofluorescence assays (IFA): For detecting proteins in fixed cells or tissues, similar to how "4H1E8 and 7H9A6 recognize HA protein from H7N9 viruses" .

• Enzyme-linked immunosorbent assay (ELISA): For quantitative detection of target proteins in solution.

• Immunoprecipitation: For isolating protein complexes from cell lysates.

• Affinity purification: Research antibodies can be "coupled to Sepharose" for one-step affinity purification of target proteins, potentially achieving "200-fold" purification with "a yield of 79%" .

How do researchers determine optimal antibody concentrations for experiments?

Determining optimal antibody concentrations requires systematic titration for each specific application:

• Titration procedure:

  • Prepare a logarithmic dilution series (e.g., 10 μg/ml to 0.01 μg/ml)

  • Test each concentration under identical experimental conditions

  • Include positive and negative controls at each concentration

  • Determine signal-to-noise ratio at each concentration

• Application-specific considerations:

  • For ELISA: Optimal concentrations typically yield OD readings in the linear range (0.5-2.0)

  • For Western blotting: Balance between specific band intensity and background

  • For neutralization assays: Determine IC50 values (e.g., "29.98 ng/μl and 13.36 ng/μl")

• Avidity influences: High-avidity antibodies like those that "reduced the binding to HA1 protein of the MAbs by 50%" only at high concentrations of chaotropic agents (e.g., 1M NaSCN) may require lower working concentrations .

What methods can be used to identify the epitope recognized by PCMP-H66 Antibody?

Epitope mapping is critical for understanding antibody function and specificity. Several approaches can be used:

• Truncation analysis: Create a series of truncated protein fragments to narrow down the binding region:

  • "We expressed a series of HA1 truncations fused to a GFP tag"

  • "In the first round, we truncated each 50 amino acids"

  • Subsequent rounds used smaller truncations: "each 12 amino acids" then "each of the three amino acids"

  • "The exact epitopes of the MAbs were finally confirmed until any amino acid missing from the epitope eliminated its reactivity"

• Peptide scanning: Synthesize overlapping peptides spanning the target protein and test antibody binding to each.

• Alanine scanning mutagenesis: Replace individual amino acids with alanine to identify critical binding residues.

• Competitive binding assays: Determine if the antibody competes with other antibodies of known epitope specificity using an "ELISA additivity test" to calculate an "additivity index (AI)" .

• Structural analysis: Use crystal structures (if available) to create "graphical representations of the epitopes" and determine their location relative to functional domains .

How can researchers determine if PCMP-H66 Antibody recognizes linear or conformational epitopes?

Distinguishing between linear and conformational epitope recognition is fundamental to understanding antibody properties:

• Denaturation tests:

  • Compare binding to native vs. denatured protein by Western blot

  • "The two MAbs react with denatured HA and HA1 proteins, which indicates that the epitopes of the two MAbs are linear"

• Reducing vs. non-reducing conditions:

  • Test binding under both conditions to evaluate the role of disulfide bonds

  • For example, "Electrophoresis under reducing conditions indicated that it consisted of one polypeptide chain"

• Peptide binding assays:

  • Linear epitopes typically bind to short synthetic peptides

  • Conformational epitopes generally require larger protein fragments with intact tertiary structure

• Circular dichroism (CD) spectroscopy:

  • Monitor changes in protein secondary structure upon antibody binding

  • Useful for conformational epitopes that induce structural changes

• Hydrogen-deuterium exchange mass spectrometry:

  • Identifies regions of altered solvent accessibility upon antibody binding

  • Particularly valuable for conformational epitopes

What techniques are used to measure antibody avidity and how does it affect experimental outcomes?

Antibody avidity (functional affinity) critically influences experimental performance:

• Avidity measurement techniques:

  • Chaotropic agent displacement: "NaSCN displacement ELISA indicated that the addition of 1 M or 1.08 M NaSCN only reduced the binding to HA1 protein of the MAbs by 50%, suggesting that 4H1E8 and 7H9A6 have high avidity"

  • Surface plasmon resonance (SPR): Measures real-time binding kinetics

  • Isothermal titration calorimetry (ITC): Provides thermodynamic binding parameters

  • Radioligand binding assays: "The binding constant between the antibody and 125I-labelled HPA66 was approximately 2.5 x 10(9) l/mol"

• Impact on experimental outcomes:

  • Higher avidity antibodies typically:

    • Require lower working concentrations

    • Produce stronger signals in detection assays

    • Show greater resistance to washing steps

    • May have superior functional effects in neutralization assays

• Avidity vs. working concentration relationship:

  • Create a standardized curve relating avidity to optimal working concentration

  • Use this relationship to predict starting concentrations for new experimental setups

How can researchers assess antibody specificity across different sample types?

Comprehensive specificity assessment requires testing across diverse sample types:

• Multiple testing methods:

  • Western blot: "The two MAbs recognize the HA protein from three strains of H7N9"

  • ELISA: Quantitative binding assays against purified proteins

  • Immunofluorescence: Cellular localization patterns

• Cross-reactivity panel testing:

  • Test against closely related proteins: "The antibody did not bind to a variety of other plasminogen activators, including 52-K and 36-K human enzymes and 48-K and 75-K murine enzymes"

  • Test against isoforms or variants: "The epitopes of two MAbs are nearly completely conserved within the H7 subtype, except for an amino acid residue at position 115"

  • Include taxonomically diverse samples when relevant

• Knockout/knockdown validation:

  • Compare antibody signals in wild-type vs. gene-modified samples

  • Provides strongest evidence for specificity

• Epitope conservation analysis:

  • Bioinformatic analysis of epitope conservation: "Sequence alignment showed that the epitopes of the MAbs are nearly completely conserved within the H7 subtype"

  • Predict cross-reactivity based on sequence homology

Can PCMP-H66 Antibody inhibit the function of its target protein?

While specific functional data for PCMP-H66 Antibody is not available, researchers should consider these approaches to assess potential inhibitory activity:

• Functional screening assays:

  • Enzyme inhibition assays: "Inhibition of the enzymatic activity of HPA66 which was complete at high antibody concentrations"

  • Receptor-ligand binding inhibition

  • Cell-based functional assays

• Mechanism determination:

  • Evaluate multiple potential mechanisms:

    • Direct active site blocking

    • Allosteric inhibition

    • Preventing protein-protein interactions

    • Blocking conformational changes: "4H1E8 and 7H9A6 inhibit the pH-dependent conformational change of HA"

• Structure-function relationships:

  • Correlate epitope location with inhibitory potential

  • Epitopes spanning functional domains often show inhibitory activity: "The epitopes of two MAbs span the RBS and the VE region"

• Dose-response characterization:

  • Determine IC50 values for quantitative comparison

  • Analyze Hill coefficients for binding cooperativity insights

What methods are used to assess the neutralizing activity of research antibodies?

For antibodies with potential neutralizing activity, multiple complementary assays should be performed:

• Virus neutralization assays:

  • "The 4H1E8 and 7H9A6 MAbs neutralized the SZ19 virus in a dose-dependent manner and displayed high neutralizing activity with IC50 values of 29.98 ng/μl and 13.36 ng/μl, respectively"

  • Plaque reduction neutralization tests (PRNT)

  • Focus reduction assays

• Mechanism-specific assays:

  • Hemagglutination inhibition (HI): "None of the two MAbs showed HI activity"

  • Fusion inhibition: "4H1E8 and 7H9A6 inhibit the low-pH induced HA-mediated cell-cell fusion"

  • ADCC (antibody-dependent cellular cytotoxicity): "The 4H1E8 and 7H9A6 MAbs do not elicit potent ADCC"

  • Viral egress inhibition: "The egress inhibition assay with oseltamivir as a positive control indicated that the 4H1E8 and 7H9A6 MAbs do not inhibit viral egress"

• Structural mechanism analysis:

  • Analyze epitope location relative to functional domains

  • Investigate conformational changes: "The 4H1E8 and 7H9A6 MAbs neutralize H7N9 virus through inhibiting the low-pH induced conformational change of HA and the HA-mediated membrane fusion"

How can researchers determine the mechanism of action for inhibitory antibodies?

Elucidating the precise mechanism of antibody-mediated inhibition requires a systematic approach:

• Mechanistic hypothesis testing:

  • Test multiple potential mechanisms using targeted assays:

    • "Inhibition assay of HA-mediated conformational change"

    • "Classical membrane fusion inhibition assay"

    • "ADCC assay"

    • "Egress inhibition assay"

• Structure-function correlation:

  • Analyze epitope location using "crystal structure of the HA protein"

  • Determine if the epitope is "localized to the lateral side of the globular head" or other functional regions

  • Assess if the epitope is "partially buried in the trimeric structure"

• Mutational analysis:

  • Create point mutations in critical residues

  • Correlate loss of binding with loss of inhibition

  • Identify specific amino acids essential for the inhibitory effect

• Temporal analysis:

  • Determine at which stage of the target protein's functional cycle the antibody acts

  • For viral targets, determine "if the antibody inhibits viral attachment, membrane fusion or egress, inhibiting conformational change of HA, and inducing ADCC activity"

What controls should be included when studying antibody-mediated inhibition?

Robust control systems are essential for reliable inhibition studies:

• Positive and negative antibody controls:

  • Known inhibitory antibodies targeting the same protein

  • Non-inhibitory antibodies targeting the same protein

  • Isotype-matched irrelevant antibodies

• Chemical inhibitor controls:

  • Small molecule inhibitors with known mechanisms (e.g., "oseltamivir as a positive control" for viral egress inhibition)

  • Serve as mechanism-specific positive controls

• Target protein controls:

  • Wild-type versus mutated target proteins

  • Related proteins from different species or variants

• Assay-specific controls:

  • For fusion inhibition: pH controls to ensure appropriate conditions

  • For enzyme inhibition: substrate and enzyme concentration controls

  • For ADCC: effector cell controls

• Concentration gradient controls:

  • Test multiple antibody concentrations to establish dose-response relationships

  • Determine IC50 values for quantitative comparison

How can PCMP-H66 Antibody be used for affinity purification of its target protein?

Antibody-based affinity purification is a powerful technique for isolating target proteins:

• Antibody immobilization strategies:

  • Direct coupling to solid supports: "With the antibody coupled to Sepharose"

  • Indirect capture via Protein A/G beads

  • Optimizing antibody orientation for maximum binding capacity

• Purification protocol optimization:

  • Buffer composition for maximum specificity

  • Sample pre-clearing steps

  • Washing stringency balance

  • Elution conditions that preserve target protein activity

• Performance evaluation:

  • Purification efficiency: "HPA66 was purified approximately 200-fold"

  • Recovery yield: "with a yield of 79%"

  • Purity assessment: "The purified HPA66 was homogeneous as evaluated by SDS-PAGE"

  • Activity retention: Functional assays post-purification

• Scale-up considerations:

  • Column format vs. batch processing

  • Reusability of the antibody-matrix

  • Sample volume handling strategies

What considerations are important when using antibodies in in vivo experiments?

In vivo applications require special considerations beyond in vitro experiments:

• Antibody format selection:

  • Full IgG vs. Fab or F(ab')2 fragments

  • Species matching to avoid immune responses

  • Isotype selection: "The MAbs are all IgG2b isotypes with κ light chains"

• Dosing optimization:

  • Dose-response studies: "4H1E8 provided 80% or 100% protection at a dose of 20 or 30 mg/kg, while 7H9A6 conferred 70% or 100% protection at a dose of 20 or 30 mg/kg"

  • Administration route: "Mice that were prophylactically inoculated with different doses of MAbs"

  • Timing: "Administered (intraperitoneally [i.p.]) antibodies at 12 h and 36 h after being challenged"

• Pharmacokinetic considerations:

  • Half-life determination

  • Tissue distribution studies

  • Clearance mechanisms

• Efficacy assessment methods:

  • Survival rates: "Mice that were prophylactically inoculated with different doses of MAbs were fully protected from sublethal challenges"

  • Physiological parameters: "Body weight recovery was more obvious at 30 mg/kg than 20 mg/kg"

  • Viral load measurements: "The viral titers in tissues from mice challenged with lethal viral doses decreased significantly"

  • Histopathological analysis: "The lung lesion of mice was significantly inhibited following treatment with MAbs"

How do researchers assess antibody therapeutics in animal models?

Comprehensive assessment of antibody therapeutics requires multi-parameter evaluation:

• Experimental design considerations:

  • Control groups: "In the control group, the mice in the sublethal dose control group partially (4/10) died by 8 days postinfection, while the mice in the lethal dose control group all died (10/10) within 9 days of infection"

  • Sample size determination: Studies used "Sixteen mice per group"

  • Blinding procedures to reduce bias

  • Statistical power calculations

• Prophylactic vs. therapeutic assessment:

  • Prophylactic protocols: "Mice that were prophylactically inoculated with different doses of MAbs"

  • Therapeutic protocols: "Administered antibodies at 12 h and 36 h after being challenged"

  • Comparative efficacy analysis

• Multi-parameter efficacy assessment:

  • Survival rates: "Antibodies at a dose of 20 or 30 mg/kg provided almost total protection"

  • Clinical scores: "Body weight recovery was more obvious at 30 mg/kg than 20 mg/kg"

  • Pathological analysis: "The pathological damage of lung tissue from mice treated with MAbs was also investigated"

  • Viral load quantification: "The viral load in the lungs and nasal turbinates of mice were examined"

• Mechanistic validation in vivo:

  • Confirm in vitro mechanism occurs in vivo

  • Assess tissue-specific effects

  • Evaluate immune system interactions

What methods can be used to study the structural interactions between antibodies and their targets?

Understanding structural interactions provides critical insights into antibody function:

• Computational modeling approaches:

  • Homology modeling based on crystal structures

  • Epitope prediction algorithms

  • Molecular dynamics simulations of antibody-antigen complexes

• Experimental structural biology techniques:

  • X-ray crystallography: "Using the crystal structure of the HA protein from H7N9 influenza viruses (PDB: 1TI8 and 6D8B)"

  • Cryo-electron microscopy

  • Hydrogen-deuterium exchange mass spectrometry

  • NMR spectroscopy for epitope mapping

• Functional validation of structural insights:

  • Site-directed mutagenesis of predicted contact residues

  • Confirmation that "the epitopes of 4H1E8 and 7H9A6 localize to the lateral side of the globular head but not the five well-defined antigenic sites"

  • Correlation of structural features with inhibitory mechanisms

• Visualization and analysis tools:

  • "Generated several graphical representations of the epitopes"

  • Structural alignment with related proteins

  • Analysis of epitope conservation in 3D space

What are common sources of false positives/negatives in antibody experiments and how can they be mitigated?

Identifying and addressing sources of experimental artifacts is critical:

• Sources of false positives:

  • Cross-reactivity with related proteins

  • Non-specific binding to matrices or solid supports

  • Endogenous peroxidase/phosphatase activity in immunoassays

  • Hook effect at high antibody or antigen concentrations

• Sources of false negatives:

  • Epitope masking by sample preparation methods

  • Target protein denaturation affecting conformational epitopes

  • Insufficient antibody concentration

  • Interfering substances in complex samples

• Mitigation strategies:

  • Comprehensive validation: "The preliminary screening included enzyme-linked immunosorbent assay and SDS-polyacrylamide gel electrophoresis (SDS-PAGE) followed by immunoblotting; the final identification was based on inhibition of the enzymatic activity"

  • Multiple detection methods: "Indirect immunofluorescence assay (IFA) and Western blot indicated that two antibodies specifically recognize HA protein"

  • Proper controls: Isotype controls, knockout/knockdown samples

  • Optimized protocols: "The epitopes recognized by two MAbs are nearly all conserved within all known H7 subtypes"

How should researchers approach antibody titration for different applications?

Systematic titration is essential for optimal antibody performance:

• Western blot titration:

  • Start with manufacturer's recommended range

  • Test 2-3 dilutions above and below recommended concentration

  • Evaluate specific signal vs. background

  • Determine minimum concentration giving clear specific signal

• ELISA titration:

  • Prepare standard curves with purified antigen

  • Test multiple antibody dilutions (typically 2-fold serial dilutions)

  • Plot titration curves to identify linear response range

  • Determine detection limits and quantification range

• Functional assay titration:

  • For neutralization assays: "The 4H1E8 and 7H9A6 MAbs neutralized the SZ19 virus in a dose-dependent manner"

  • Calculate IC50 values: "IC50 values of 29.98 ng/μl and 13.36 ng/μl"

  • Determine minimum inhibitory concentration

  • Assess maximum inhibition achievable

• Application-specific considerations:

  • IFA typically requires higher concentrations than Western blot

  • Flow cytometry may require higher concentrations than ELISA

  • Account for sample complexity and target abundance

What alternatives exist when antibody-based detection yields inconsistent results?

When facing inconsistent antibody performance, consider these alternatives:

• Alternative antibody formats:

  • Test different clones targeting different epitopes

  • Try polyclonal instead of monoclonal antibodies or vice versa

  • Consider different species of origin

  • Test different isotypes: "The MAbs are all IgG2b isotypes with κ light chains"

• Non-antibody detection methods:

  • Mass spectrometry-based proteomics

  • RNA-based detection (RT-PCR, RNA-seq)

  • Activity-based protein profiling

  • Aptamer-based detection systems

• Enhanced detection strategies:

  • Signal amplification methods

  • More sensitive detection systems

  • Sample enrichment techniques

  • Proximity ligation assays

• Protocol optimization approaches:

  • Modify sample preparation: "SDS-polyacrylamide gel electrophoresis (SDS-PAGE) followed by immunoblotting"

  • Adjust blocking conditions

  • Optimize incubation times and temperatures

  • Test different detection systems

How can researchers optimize antibody performance in challenging experimental conditions?

Optimizing antibody performance often requires systematic troubleshooting:

• Sample preparation optimization:

  • Lysis buffer composition for protein extraction

  • Fixation protocols for immunohistochemistry

  • Denaturation conditions for Western blot

  • Blocking agents to reduce background

• Buffer system modifications:

  • pH optimization based on antibody properties

  • Salt concentration adjustments

  • Detergent type and concentration

  • Protein stabilizers and preservatives

• Incubation condition optimization:

  • Temperature effects on binding kinetics

  • Time course experiments to determine optimal incubation periods

  • Static vs. dynamic binding conditions

  • Fresh vs. frozen samples

• Documentation and standardization:

  • Detailed protocol recording

  • Lot-to-lot comparison of antibody performance

  • Reference standards for quantitative assays

  • Quality control measures for reproducibility